Complement-endothelial cell interactions: Pathophysiological implications

Molecular Immunology

Volumn 36, Issue 4-5, 1999, Pages 261-268

  Tedesco, F ^a   Fischetti, F ^c   Pausa, M ^a   Dobrina, A ^a   Sim, R B ^b   Daha, M R ^c  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT;

ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD VESSEL TONE; CELL INTERACTION; COMPLEMENT SYSTEM; CONFERENCE PAPER; ENDOTHELIUM CELL; INFLAMMATION; ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; REPERFUSION; XENOTRANSPLANTATION;

EID: 0032975035     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(99)90054-8     Document Type: Conference Paper

References (75)

1. Agostoni A., Gardinali M., Frangi D., Cafaro C., Conciato L., Sponzilli C., Salvioni A., Cugno M., Cicardi M. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator. Circulation. 90:1994;2666-2670.
2. Amsterdam E.A., Stahl G.L., Pan H-L., Rendig S.V., Fletcher M.P., Longhurst J.C. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am. J. Physiol. 268:1995;H448-H457.
3. Asch A.S., Kinoshita T., Jaffe E.A., Nussenzweig V. Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J. Exp. Med. 163:1986;221-226.
4. Benzaquen L.R., Nicholson-Weller A., Halperin J.A. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J. Exp. Med. 179:1994;985-992.
5. Berge V., Johnson E., Hogasen K., Hetland G. Human umbilical vein endothelial cells synthesize S-protein (vitronectin) in vitro. Scand. J. Immunol. 36:1992;119-123.
6. Berge V., Johnson E., Hogasen K. Clusterin and the terminal complement pathway synthesized by human umbilical vein endothelial cells are closely linked when detected on co-cultured agarose beads. APMIS. 105:1997;17-24.
7. Bhakdi S., Dorweiler B., Kirchmann R., Torzewski J., Weise E., Tranum-Jensen J., Walev I., Wieland E. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J. Exp. Med. 182:1995;1959-1971.
8. Brooimans R.A., Hiemstra P.S., van der Ark A.A.J., Sims R.B., van Es L.A., Daha M.R. Biosynthesis of complement factor H by human umbilical vein endothelial cells. Regulation by T cell growth factor and IFN-γ J. Immunol. 142:1989;2024-2030.
9. Brooimans R.A., van der Ark A.A.J., Buurman W.A., van Es L.A., Daha M.R. Differential regulation of complement factor H and C3 production in human umbilical vein endothelial cells by IFN-γ and IL-1. J. Immunol. 144:1990;3835-3840.
10. Buerke M., Murohara T., Lefer A.M. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation. 91:1995;393-402.
11. Bulla R., Pausa M., Vecile E., Dobrina A., Tedesco F. Activation of endothelial cells by the inactive terminal complement complex promotes adherence and transendothelial migration of PMN. Mol. Immunol. 35:1998;407. (Abstract).
12. Christiansen V.J., Sims P.J., Hamilton K.K. Complement C5b-9 increases plasminogen binding and activation on human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 17:1997;164-171.
13. Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P., Pober J.S., Wick T.M., Konkle B.A., Schwartz B.S., Barnathan E.S., McCrae K.R., Hug B.A., Schmidt A.M., Stern D.M. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 91:1998;3527-3561.
14. Collard C.D., Väkevä A., Büküsoglu C., Zünd G., Sperati C.J., Colgan S.P., Stahl G.L. Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway. Circulation. 96:1997;326-333.
15. Daha M.R., Miltenburg A.M., Hiemstra P.S., Klar-Mohamad N., van Es L.A., Van Hinsbergh V.W. The complement subcomponent C1q mediates binding of immune complexes and aggregates to endothelial cells in vitro. Eur. J. Immunol. 18:1988;783-787.
16. Daha M.R., Dunn L., van den Berg R., Muizertde Lange Y., Gerritsen A., van Es L.A. Isolation and function of a human endothelilal cell C1q receptor. Mediators of Inflammation. 2:1993;447-452.
17. Diamond L.E., McCurry K.R., Martin M.J., McClellan S.B., Oldham E.R., Platt J.L., Logan J.S. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation. 61:1996;1241-1249.
18. Dimmeler S., Zeiher C.H. Apoptosis of endothelial cells. Contribution to the pathophysiology of atherosclerosis? Eur. Cytokine Netw. 9:1998;697-698.
19. Foreman K.E., Vaporciyan A.A., Bonish B.K., Jones M.L., Johnson K.J., Glovsky M.M., Eddy S.M., Ward P.A. C5a-induced expression of P-selectin in endothelial cells. J. Clin. Invest. 94:1994;1147-1155.
20. Gasque P., Singhrao S.K., Neal J.W., Gotze O., Morgan B.P. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am. J. Pathol. 150:1997;31-41.
21. Good A.H., Cooper D.K., Malcolm A.J., Ippolito R.M., Koren E., Neethling F.A., Ye Y., Zuhdi N., Lamontagne L.R. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant. Proc. 24:1992;559-562.
22. Gulati P., Lemercier C., Guc D., Lappin D., Whaley K. Regulation of the synthesis of C1 subcomponents and C1-inhibitor. Behring. Inst. Mitt. 93:1993;196-203.
23. Hamilton K.K., Hattori R., Esmon C.T., Sims P.J. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J. Biol. Chem. 265:1990;3809-3814.
24. Hamilton K.K., Ji Z., Rollins S., Stewart B.H., Sims P.J. Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59. Blood. 76:1990;2572-2577.
25. Hattori R., Hamilton K.K., Fugate R.D., McEver R.P., Sims P.J. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J. Biol. Chem. 264:1989;7768-7771.
26. Haviland D.L., McCoy R.L., Whitehead W.T., Akama H., Molmenti E.P., Brown A., Haviland J.C., Parks W.C., Perlmutter D.H., Wetsel R.A. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J. Immunol. 154:1995;1861-1869.
27. Hinchliffe S.J., Rushmere N.K., Hanna S.M., Morgan B.P. Molecular cloning and functional characterization of the pig analogue of CD59: relevance to xenotransplantation. J. Immunol. 60:1998;3924-3932.
28. Hindmarsh E.J., Marks R.M. Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal of overlying endothelial cells. J. Immunol. 60:1998;6128-6136.
29. Ito W., Schäfer H.J., Bhakdi S., Klask R., Hansen S., Schaarschmidt S., Schofer J., Hugo F., Hamdoch T., Mathey D. Influence of the terminal complement-complex on reperfusion injury, no-reflow and arrhythmias: a comparison between C6-competent and C6-deficient rabbits. Cardiovasc. Res. 32:1996;294-305.
30. Jaffe E.A. Biochemistry, immunology and cell biology of endothelium. Colman R.W., Hirsh J., Marder V.J., Saltzman E.W. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 1994;718-744 Lippincott Co, Philadelphia.
31. Johnson E., Hetland G. Human umbilical vein endothelial cells synthesize functional C3, C5, C6, C8 and C9 in vitro. Scand. J. Immunol. 33:1991;667-671.
32. Julen N., Dauchel H., Lemercier C., Sims R.B., Fontaine M., Ripoche J. In vitro biosynthesis of complement factor I by human endothelial cells. Eur. J. Immunol. 22:1992;213-217.
33. Kilgore K.S., Shen J.P., Miller B.F., Ward P.A., Warren J.S. Enhancement by the complement membrane attack complex of tumor necrosis factor-α-induced endothelial cell expression of E-selectin and ICAM-1. J. Immunol. 155:1995;1434-1441.
34. Kilgore K.S., Schmid E., Shanley T.P., Flory C.M., Maheswari V., Tramontini N.L., Cohen H., Ward P.A., Friedl H.P., Warren J.S. Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kB activation. Am. J. Pathol. 150:1997;2019-2031.
35. Kilgore K.S., Park J.L., Tanhehco E.J., Booth E.A., Marks R.M., Lucchesi B.R. Attenuation of interleukin-8 expression in C6-deficient rabbits after myocardial ischemia/reperfusion. J. Mol. Cell. Cardiol. 30:1998;75-85.
36. Kroshus T.J., Rollins S.A., Dalmasso A.P., Elliott E.A., Matis L.A., Squinto S.P., Bolman R.M. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation. 60:1995;1194-1202.
37. Lambrigts D., Sachs D.H., Cooper D.K.C. Discordant organ xenotransplantation in primates. Transplantation. 66:1998;547-561.
38. Langeggen H., Pausa M., Johnson E., Tedesco F. Human umbilical vein endothelial cells synthesize complement factor C7 in vitro. Mol. Immunol. 35:1998;370. (Abstract).
39. Lopes-Virella M.F., Virella G. Atherosclerosis and autoimmunity. Clin. Immunol. Immunopathol. 73:1994;155-167.
40. Lorenzon P., Vecile E., Nardon E., Ferrero E., Harlan J.M., Tedesco F., Dobrina A. Endothelial cell E- and P-selectin and vascular cell adhesion molecule-1 function as signalling receptors. J. Cell Biol. 142:1998;1381-1391.
41. Lozada C., Levin R.I., Huie M., Hirschhorn R., Naime D., Whitlow M., Recht P.A., Golden B., Cronstein B.N. Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc. Natl. Acad. Sci. USA. 92:1995;8378-8382.
42. Lübbe A.S., Garrison R.N., Harris P.D. Endothelium-dependent microvascular responses to activated complement. J. Surg. Res. 57:1994;654-660.
43. Lucchesi B.R., Kilgore K.S. Complement inhibitors in myocardial ischemia/reperfusion injury. Immunopharmacology. 38:1997;27-42.
44. Mathey D., Schofer J., Schäfer H.J., Hamdoch T., Joachim H.C., Ritgen A., Hugo F., Bhakdi S. Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. Eur. Heart J. 15:1994;418-423.
45. McNearney T., Ballard L., Seya T., Atkinson J.P. Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. J. Clin. Invest. 84:1989;538-545.
46. Mevorach D., Mascarenhas J.O., Gershov D., Elkon K.B. Complement-dependent clearance of apoptotic cells by human macrophages. J. Exp. Med. 188:1998;2313-2320.
47. Mugge A., Lopez J.A., Heistad D.D., Lichtlen P.R. Vasoconstriction in response to activated leukocytes: implications for vasospasm. Eur. Heart J. 14:1993;87-92(Supplement I).
48. p, the C1q receptor that enhances phagocytosis, is detected specifically in human cells of myeloid lineage, endothelial cells, and platelets. J. Immunol. 160:1998;1929-1935.
49. Niculescu F., Rus H.G., Vlaicu R. Activation of the human terminal complement pathway in atherosclerosis. Clin. Immunol. Immunopathol. 45:1987;147-155.
50. Peerschke E.I.B., Malhotra R., Ghebrehiwet B., Reid K.B.M., Willis A.C., Sim R.B. Isolation of a human endothelial cell C1q receptor (C1qR). J. Leukoc. Biol. 53:1993;179-184.
51. Peerschke E.I.B., Smyth S.S., Teng E.I., Dalzell M., Ghebrehiwet B. Human umbilical vein endothelial cells possess binding sites for the globular domain of C1q. J. Immunol. 157:1996;4154-4158.
52. Platt J.L., Dalmasso A.P., Lindman B.J., Ihrcke N.S., Bach F.H. The role of C5a and antibody in the release of heparan sulfate from endothelial cells. Eur. J. Immunol. 21:1991;2887-2890.
53. Ripoche J., Mitchell J.A., Erdei A., Madin C., Moffatt B., Mokoena T., Gordon S., Sim R.B. Interferon γ induces synthesis of complement alternative pathway proteins by human endothelial cells in culture. J. Exp. Med. 168:1988;1917-1922.
54. Saadi S., Holzknecht R.A., Patte C.P., Stern D.M., Platt J.L. Complement-mediated regulation of tissue factor activity in endothelium. J. Exp. Med. 182:1995;1807-1814.
55. Saadi S., Platt J.L. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J. Exp. Med. 181:1995;21-31.
56. Sata M., Walsh K. Oxidized LDL activates Fas-mediated endothelial cell apoptosis. J. Clin. Invest. 102:1998;1682-1689.
57. Schäfer H., Mathey D., Hugo F., Bhakdi S. Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J. Immunol. 137:1986;1945-1949.
58. Seifert P.S., Kazatchkine M.D. The complement system in atherosclerosis. Atherosclerosis. 73:1988;91-104.
59. Seifert P.S., Hugo F., Hansson G.K., Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab. Invest. 60:1989;747-754.
60. Seifert P.S., Hugo F., Tranum-Jensen J., Zâhringer U., Muhly M., Bhakdi S. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J. Exp. Med. 172:1990;547-557.
61. Springer T.A. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu. Rev. Physiol. 57:1995;827-872.
62. Stahl G.L., Reenstra W.R., Frendl G. Complement-mediated loss of endothelium-dependent relaxation of porcine coronary arteries. Role of the terminal membrane attack complex. Circ. Res. 76:1995;575-583.
63. Tedesco F., Pausa M., Nardon E., Introna M., Mantovani A., Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J. Exp. Med. 185:1997;1619-1627.
64. Torzewski J., Bowyer D.E., Waltenberger J., Fitzsimmons C. Processes in atherogenesis: complement activation. Atherosclerosis. 132:1997;131-138.
65. Torzewski M., Klouche M., Hock J., Meßner M., Dorweiler B., Torzewski J., Gabbert H.E., Bhakdi S. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler. Thromb. Vasc. Biol. 18:1998;369-378.
66. Tsuji S., Kaji K., Nagasawa S. Activation of the alternative pathway of human complement by apoptotic human umbilical vein endothelial cells. J. Biochem. 116:1994;794-800.
67. Väkevä A., Laurila P., Meri S. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab. Invest. 67:1992;608-616.
68. Väkevä A.P., Agah A., Rollins S.A., Matis L.A., Li L., Stahl G.L. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation. 97:1998;2259-2267.
69. Van den Berg R.H., Faber-Krol M.C., Sim R.B., Daha M.R. The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J. Immunol. 161:1998;6924-6930.
70. Venneker G.T., van den Hoogen F.H.J., Boerbooms A.M.T., Bos J.D., Asghar S.S. Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage. Lab. Invest. 70:1994;830-835.
71. Warren H.B., Pantazis P., Davis P.F. The third component of complement is transcribed and secreted by cultured human endothelial cells. Am. J. Pathol. 129:1987;9-13.
72. Weiser M.R., Williams J.P., Moore F.D., Kobzik L., Ma M., Hechtman H.B., Carroll M.C. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J. Exp. Med. 183:1996;2343-2348.
73. Weisman H.F., Barthow T., Leppo M.K., Marsh H.C., Carson G.R., Concino M., Boyle M.P., Roux K.H., Weisfeldt M.L., Fearon D.T. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 249:1990;146-151.
74. Wick G., Schett G., Amberger A., Kleindienst R., Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol. Today. 16:1995;27-33.
75. Würzner R., Joysey V.C., Lachmann P.J. Complement component C7. Assessment of in vivo synthesis after liver transplantation reveals that hepatocytes do not synthesize the majority of human C7. J. Immunol. 152:1994;4624-4629.